SCHEDULE 13G/A: BlackRock Amends Stake in Viking Therapeutics, Disclosing 4.5% Ownership

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.5% beneficial ownership stake in Viking Therapeutics, Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Viking Therapeutics, Inc.
• As of March 31, 2025, BlackRock, Inc. beneficially owns an aggregate of 5,031,511 shares of Viking Therapeutics, Inc. Common Stock.
• This ownership represents 4.5% of the total class of securities outstanding.
• BlackRock holds sole voting power over 4,807,647 shares and sole dispositive power over 5,031,511 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• BlackRock, Inc. is classified as a parent holding company or control person for the purpose of this filing.
• The beneficial ownership is aggregated from various BlackRock business units and subsidiaries, none of which individually hold 5% or greater of the outstanding shares.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a routine regulatory disclosure. BlackRock's continued holding of a significant stake, albeit below the 5% threshold, and its certification of passive investment, suggests stability and ongoing confidence in Viking Therapeutics, Inc. from a major institutional investor.

Positives

• BlackRock's continued holding of a significant stake in Viking Therapeutics, Inc. (4.5%) indicates ongoing institutional confidence in the company.
• The certification that shares are held in the ordinary course of business suggests a stable, passive investment, which can be viewed positively by other investors seeking long-term stability.

Negatives

• The 4.5% ownership is below the 5% threshold that would trigger more detailed reporting requirements (e.g., Schedule 13D), limiting deeper insights into BlackRock's specific investment thesis or intentions beyond passive holding.

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance regarding Viking Therapeutics, Inc.'s future performance or BlackRock's future investment intentions beyond the certification that shares are held in the ordinary course of business.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

This filing reflects a routine disclosure by a major institutional investor, BlackRock, Inc., regarding its passive stake in Viking Therapeutics, Inc. It is common for large asset managers to hold significant, but non-controlling, positions across numerous publicly traded companies as part of their diversified investment strategies. This particular filing does not provide specific insights into the biotechnology or pharmaceutical industry trends, but rather confirms BlackRock's continued presence as a shareholder.

Comparison to Industry Standards

• This document is a standard Schedule 13G filing, which is a regulatory requirement for institutional investors acquiring more than 5% (or amending a previous filing) of a company's stock, but not seeking to control the company.
• BlackRock's 4.5% stake in Viking Therapeutics, Inc. is a typical passive investment size for a large asset manager, aligning with common institutional portfolio diversification practices.
• There are no specific comparable companies, projects, or results mentioned in this filing to assess performance against industry benchmarks, as it focuses solely on ownership disclosure.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, confirming it is a passive investment held in the ordinary course of business.
• Management: Awareness of BlackRock's continued, passive ownership, which may influence perceptions of institutional support.

Next Steps

• No specific future actions or milestones for Viking Therapeutics, Inc. are mentioned in this ownership disclosure.
• BlackRock will continue to monitor its investment and file updates as required by SEC regulations if its ownership percentage changes significantly.

Key Dates

Keywords

BlackRock, Viking Therapeutics, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Management